<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="773">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333654</url>
  </required_header>
  <id_info>
    <org_study_id>EFC16855</org_study_id>
    <secondary_id>2020-001269-35</secondary_id>
    <secondary_id>U1111-1249-6168</secondary_id>
    <nct_id>NCT04333654</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine in Outpatient Adults With COVID-19</brief_title>
  <official_title>A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral
      load in outpatient adults with COVID-19

      Secondary Objectives:

        -  To assess the effect of hydroxychloroquine versus placebo on clinical signs and symptoms
           and progression of disease in outpatient adults with COVID-19

        -  To assess the safety and tolerability of hydroxychloroquine in outpatient adults with
           COVID-19
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study per participant will be around 18 days (1 or 2 days of screening
      followed by a 10-day treatment period and a 4 to 6 days follow-up period)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2020</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)</measure>
    <time_frame>Baseline to Day 3</time_frame>
    <description>Viral load assessed by PCR from a nasopharyngeal swab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)</measure>
    <time_frame>Baseline to Day 3</time_frame>
    <description>Viral load assessed by PCR from a nasopharyngeal swab - 2. Viral load assessed by PCR from a nasopharyngeal swab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 5 in nasopharyngeal SARS-CoV-2 viral load</measure>
    <time_frame>Baseline to Day 5</time_frame>
    <description>Viral load assessed by PCR from a nasopharyngeal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants by PCR result status (positive or negative)</measure>
    <time_frame>Baseline to end of study (Day14)</time_frame>
    <description>Viral load assessed by PCR from a nasopharyngeal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with COVID-19 symptoms by severity</measure>
    <time_frame>Baseline to end of study (Day14)</time_frame>
    <description>COVID-19 symptoms (feverishness, sore throat, cough, shortness of breath, myalgias) will be scored by the participant on a 4-point scale ( 0 =none; 1 = mild; 2 = moderate; 3 = severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of COVID-19 Symptoms</measure>
    <time_frame>Baseline to end of study (Day14)</time_frame>
    <description>COVID-19 symptoms (feverishness, sore throat, cough, shortness of breath, myalgias) will be scored by the participant on a 4-point scale ( 0 =none; 1 = mild; 2 = moderate; 3 = severe). Resolution of a symptom is defined as when a symptom previously scored â‰¥ 1 on the scale is scored as 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever</measure>
    <time_frame>Baseline to end of study (Day14)</time_frame>
    <description>Resolution of fever defined as the first day of 2 consecutive daily temperatures &lt; 37.7 C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with resolution of fever</measure>
    <time_frame>Baseline to end of study (Day14)</time_frame>
    <description>Resolution of fever defined as the first day of 2 consecutive daily temperatures &lt; 37.7 C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants hospitalized</measure>
    <time_frame>Baseline to end of study (Day14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Baseline to end of study (Day14)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine, loading dose on day 1 followed by a daily maintenance dose during 9 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine SAR321068</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Participants with diagnosis of COVID-19 via nasopharyngeal swab Polymerase Chain
             Reaction (PCR)

          -  Time between onset of symptoms and enrollment is 72 hours or less

        Exclusion criteria:

          -  Severe COVID-19 requiring inpatient treatment

          -  Women who are pregnant or breastfeeding

          -  Concurrent antimicrobial therapy

          -  Known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds

          -  Hydroxychloroquine use within 2 months before enrollment

          -  History of severe skin reactions such as Sevens-Johnson syndrome and toxic epidermal
             necrolysis

          -  History of retinopathy

          -  History of arrythmia, concurrent use of anti-arrhythmic drugs, or family history of
             sudden cardiac death

          -  History of severe renal disease (treatment with dialysis or phosphate binders) or
             hepatic impairment

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2501001</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2501002</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5281001</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

